Sarepta Therapeutics, Inc.
EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY
Last updated:
Abstract:
Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.
Status:
Application
Type:
Utility
Filling date:
30 Apr 2021
Issue date:
4 Nov 2021